Clinical Case Discussion Forum

Subscribe to the Clinical Case Discussion Forum

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

CML and Breast cancer

Start
Prev
1
Next
End

Irine Datikashvili-David
Topic Author

2 months 3 weeks ago - 2 months 3 weeks ago #1957 by Irine Datikashvili-David

CML and Breast cancer was created by Irine Datikashvili-David

50 years old woman was diagnosed CML chronic phase in February 2024. BCR-ABL expression 40%. In History 2015 invasive ductal breast cancer G2, ER +, PR+ , ki 67- 3-4%, HER2/neu -2+, Ki 67 3-4%, CISH negative. Radical mastectomy followed by radiotherapy and 2 month hormonotherapy have been performed. In 2022 Breast cancer relapse pT2NxM0, Ist A stage. Tampxiphen was given. In April 2024 3rd relapse- right breast invasive ductal carcinoma (G2), ER-80%, PR 50%, ki 67- 20%. Status post radical mastectomy pT1c (multi) N2 (MTS in 6 out of 14 lymph nodes).

Since February 2024 the patient is given Imatinib Mesilate after 2 month treatme hematological response is confirmed( intially WBC count was 104 x109/l); BCR -ABL expression was 20 %.

The patient needs aggressive chemotherapy for breast cancer. Planned chemotherapy drugs interact with imatinib .

What will be your consideration about continuation Imatinib or will it be more reasonable to stop Gliveec and check BCR once a month ?

Last edit: 2 months 3 weeks ago by arlene.

Massimo Breccia
Topic Author

2 months 3 weeks ago #1958 by Massimo Breccia

Replied by Massimo Breccia on topic CML and Breast cancer

We have treated some patients with CML and second neoplasia. During the chemotherapy we temporarily stopped TKI, considering that chemo probably acts also on the Ph+ stem cells. I suggest, if possible, to alternate TKI in the period between one cycle and another of chemo for breast cancer. It’s important to strictly monitor the molecular MRD.

Ehab ATallah
Topic Author

2 months 3 weeks ago #1959 by Ehab ATallah

Replied by Ehab ATallah on topic CML and Breast cancer

Would really depend on the chemotherapy planned. e.g
TKIs have been safely combined with HyperCVAD, so combining with AC for example would be safe.
There is a phase I of imatnib with taxol (Pishvaian MJ et al. A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. Cancer Chemother Pharmacol. 2012 Dec;70(6):843-53. doi: 10.1007/s00280-012-1969-9. Epub 2012 Sep 27. PMID: 23014737; PMCID: PMC3703247.)

Ehab

Start
Prev
1
Next
End

Moderators: Nicola, arlene

Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK